



Universiteit
Leiden
The Netherlands

Sizing strategy and implant considerations for the avalu valve

Moront, M.G.; Sabik, J.F.; Reardon, M.J.; Dagenais, F.; Lange, R.; Walther, T.; ... ; Klautz, R.J.M.

Citation

Moront, M. G., Sabik, J. F., Reardon, M. J., Dagenais, F., Lange, R., Walther, T., ... Klautz, R. J. M. (2020). Sizing strategy and implant considerations for the avalu valve. *The Annals Of Thoracic Surgery*, 110(6), E551-E553. doi:10.1016/j.athoracsur.2020.04.103

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3183997>

Note: To cite this publication please use the final published version (if applicable).

Sizing Strategy and Implant Considerations for the Avalu Valve



Michael G. Moront, MD, Joseph F. Sabik III, MD, Michael J. Reardon, MD, Francois Dagenais, MD, Rüdiger Lange, MD, Thomas Walther, MD, PhD, Faraz Kerendi, MD, and Robert J. M. Klautz, MD, PhD

Department of Cardiothoracic Surgery, ProMedica Toledo Hospital, Toledo, Ohio; Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio; Department of Cardiovascular Surgery, DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas; Department of Cardiac Surgery, University Institute of Cardiology and Pulmonology of Quebec (IUCPQ), University of Laval, Québec, Canada; Department of Cardiovascular Surgery and the INSURE-Institute for Translational Cardiac Surgery, German Heart Centre Munich, Munich, Germany; Department of Cardiac, Thoracic, and Thoracic Vascular Surgery, University Hospital Frankfurt, Frankfurt, Germany; Division of Cardiac Surgery, Heart Hospital of Austin, Austin, Texas; and Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, Netherlands

Hemodynamic performance of the Avalu valve through 3 years after implant is comparable to that of contemporary surgical bioprostheses. Many variables affect hemodynamic outcomes, including surgical technique. This article describes our experience with the Avalu

bioprosthesis and strategies to achieve optimal hemodynamic performance.

(Ann Thorac Surg 2020;110:e551-3)

© 2020 by The Society of Thoracic Surgeons

The Pericardial Surgical Aortic Valve Replacement (PERIGON) Pivotal Trial (NCT02088554) is a prospective investigation of the Avalu bioprosthesis (Medtronic, Minneapolis, MN). The stent of the valve is composed of a nondeformable base frame and a superimposed frame with flexible posts.¹ The leaflets, made of bovine pericardial tissue treated with α -amino oleic acid, are mounted within the stent. The valve is commercially available in several countries in sizes of 19 to 27 mm.

Previous analyses through 3 years of follow-up demonstrated hemodynamic performance and clinical outcomes comparable to those of other surgical valves.¹⁻³ Although multiple patient factors influence hemodynamic performance after valve implantation, surgical technique is important to consider. This article describes our experience with the Avalu bioprosthesis and the sizing strategy and implant technique to achieve optimal hemodynamic outcomes.

Technique

Valve Implantation

The valve can be implanted through a full sternotomy, partial or ministernotomy, or right anterior thoracotomy. A hockey stick-type incision, angling for the midportion of the noncoronary sinus, is optimal. If the sinotubular junction (STJ) needs to be divided to facilitate valve placement, extend the aortotomy into and through the junction above the level of the noncoronary sinus and

open the STJ directly (Figure 1A). In routine cases, the aortotomy does not need to extend deep into the non-coronary sinus. If the aortic root is dilated and the ascending aorta requires replacement with a tube graft, a transverse aortotomy may be more appropriate. In patients with a narrow STJ and a small annulus, enlarge the STJ and annulus with a prosthetic patch. Aortic valve replacement is facilitated by retracting the distal ascending aorta with a traction suture and placing 3 stay sutures in the top of the commissural pillars to support and stabilize the aortic root. After debridement of the root and annulus, size the annulus to select a valve size.

Use only the Avalu sizer with the Avalu valve (Figure 1B). The barrel end approximates the valve's internal diameter and indicates the maximum size that may fit. The replica end represents the true valve size in the implanted position (Figure 1B). The replica is the most accurate predictor of the size that corresponds to the patient's annulus and root and should always be used to select the valve size. The replica should fit relatively easily

Dr Moront discloses a financial relationship with Medtronic, Edwards Lifesciences, LSI, and Atricure; Drs Sabik, Reardon, and Dagenais with Medtronic; Dr Lange with Medtronic and HighLife Medical; Dr Kerendi and Prof Klautz with Medtronic, Edwards Lifesciences, and LivaNova.

Accepted for publication Apr 18, 2020.

Address correspondence to Dr Moront, Department of Cardiothoracic Surgery, ProMedica Toledo Hospital, 2109 Hughes Dr #720, Toledo, OH 43606; email: michael.moront@promedica.org.

The Video can be viewed in the online version of this article [<https://doi.org/10.1016/j.athoracsur.2020.04.103>] on <http://www.annalsthoracicsurgery.org>





Figure 1. (A) Opening the sinotubular junction. (B) Avalus sizer. The replica end represents the valve in the final implanted position and should always be used for valve size selection. Reproduced with permission of Medtronic, Inc. (C) Appropriately sized Avalus valve. Minimal tissue is a good indicator that the valve size is appropriate.

Figure 2. (A) Mean aortic gradient and (B) effective orifice area 1 year after implant in the Pericardial Surgical Aortic Valve Replacement Pivotal Trial.²



through the STJ and into the root. If the replica moves too easily through the annulus, the valve is too small. If the replica fits tightly into the aortic root and there is significant protrusion of sinus tissue underneath the sizer, the valve is too large. A correctly sized valve fits firmly in the root with minimal to no sinus tissue protruding into the left ventricular outflow tract lumen (Figure 1C; Video). It is important to gauge the amount of visible annular tissue when looking through the sizer. Minimal tissue is a good indicator that the size is appropriate. Too much tissue indicates that the size is too large even though the replica may fit into the root. Avoid using indexed effective orifice area (EOA) charts for valve size selection because these have limited ability to predict prosthesis–patient mismatch.⁴ Also, avoid oversizing to maximize hemodynamics and durability.

Noneverting pledgeted mattress sutures or simple interrupted sutures may be used. Place sutures with a generous bite into the cuff close to the stent to facilitate cuff folding and valve seating. The valve is designed to be implanted in the supra-annular position. We routinely place 9 to 12 noneverting pledgeted mattress sutures in a subannular position and lower the valve into position in the aortic root. Care should be taken when inserting the valve into a calcified or rigid aortic root.

Hand-tied knots or titanium auto-knotting devices may be used to secure sutures. Leaving the valve holder in place allows for safer manipulation of the valve while tying or using an auto-knotting device. Once all sutures are secured, the holder is removed. On rare occasions, the aortotomy may be too tight to close once the valve is seated. In these cases, an aortic root patch closure may be performed.

Comment

Sizing and surgical technique are critical to hemodynamic and durability outcomes after surgical aortic valve replacement.⁵ Undersizing can result in implantation of a prosthesis that is too small for a patient's cardiac output requirements, producing patient–prosthesis mismatch, whereas oversizing may increase aortic pressure gradients, decrease EOAs, and diminish the effect of increased flow rates, causing premature prosthetic valve degeneration.⁶ Use of the replica end of the sizer to select the valve size is critical.⁵

Adherence to these sizing considerations resulted in an overall mean gradient and EOA at 1 year after implant of 12.5 ± 4.4 mm Hg ($n = 518$) and 1.5 ± 0.4 cm² ($n = 394$), respectively, in the PERIGON Pivotal Trial (Figure 2),² outcomes that have remained stable through 3 years of follow-up³ and are comparable to those from the contemporary COMMENCE (Prospective, nOn-randomized, Multicenter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform) study.⁷

An important consideration when choosing an aortic bioprosthesis is long-term durability, which is influenced

by many factors, including valve design. The firm base frame of the Avalus valve will maintain its round shape, including in the elliptical bicuspid valve annulus. The flexible stent posts relieve mechanical stress on the leaflets, and in our experience, provide additional space for knot-tying. The valve has a low profile to reduce the risk of coronary obstruction. The leaflets are mounted internally within the stent, a construction associated with longer durability than externally mounted leaflets.⁸

The PERIGON Pivotal Trial has demonstrated favorable hemodynamic performance of the Avalus valve during up to 3 years of follow-up. As with any surgical valve replacement, valve sizing strategy and implant technique are important to achieve optimal hemodynamics and long-term durability. Use of the replica end of the sizer is critical to select the appropriate valve size, and oversizing should be avoided.

The PERIGON Pivotal trial is sponsored by Medtronic. Dr Sabik is a member of the Cardiac Surgery Advisory Board, is the North American Primary Investigator (PI) for the PERIGON Pivotal Trial, and teaches mitral valve repair techniques for Medtronic. He is also the local PI for the Intuity Trial and the North American Surgical PI for the EXCEL Trial. Timothy Ryan provided a technical review of the manuscript. Julie A. Linick reviewed the draft of the manuscript and created figures under the direction of the lead author. Both are employees of Medtronic.

References

1. Klautz RJM, Kappetein AP, Lange R, et al. Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis. *Eur J Cardiothorac Surg*. 2017;52:425-431.
2. Sabik JF III, Rao V, Lange R, et al. One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. *J Thorac Cardiovasc Surg*. 2018;156:1368-1377.
3. Klautz RJM, Vriesendorp MD, Dagenais F, et al. Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis [e-pub ahead of print]. *J Thorac Cardiovasc Surg*. <https://doi.org/10.1016/j.jtcvs.2019.10.095>, accessed February 11, 2020.
4. Vriesendorp MD, de Lind van Wijngaarden RAF, Head SJ, et al. The fallacy of indexed effective orifice area charts to predict prosthesis–patient mismatch after prosthesis implantation. *Eur Heart J Cardiovasc Imaging*. 2020;21:1116-1122.
5. Durko AP, Head SJ, Pibarot P, et al. Characteristics of surgical prosthetic heart valves and problems around labeling: a document from the European Association for Cardio-Thoracic Surgery (EACTS)–The Society of Thoracic Surgeons (STS)–American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. *J Thorac Cardiovasc Surg*. 2019;158:1041-1054.
6. Cleveland JD, Bowdish ME, Eberhardt CE, et al. Evaluation of hemodynamic performance of aortic valve bioprostheses in a model of oversizing. *Ann Thorac Surg*. 2017;103:1866-1876.
7. Puskas JD, Bavaria JE, Svensson LG, et al. The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue. *Eur J Cardiothorac Surg*. 2017;52:432-439.
8. Hickey GL, Bridgewater B, Grant SW, et al. National registry data and record linkage to inform postmarket surveillance of prosthetic aortic valve models over 15 years. *JAMA Intern Med*. 2017;177:79-86.